<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671459</url>
  </required_header>
  <id_info>
    <org_study_id>KB 2020</org_study_id>
    <nct_id>NCT04671459</nct_id>
  </id_info>
  <brief_title>TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine</brief_title>
  <acronym>TaRRGET</acronym>
  <official_title>A Phase II Trial of Tumor Treating Fields (TTFields) Concomitant With Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Franciszek Lukaszczyk Memorial Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NovoCure GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Prof. Franciszek Lukaszczyk Memorial Oncology Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients will receive TTFields therapy and additionally Stereotactic Radiosurgery .&#xD;
      Radiosurgery will be based on MRI and FET-PET or MRI alone. Addition of FET-PET will be&#xD;
      preferred option.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Almost all GBM patients experience recurrent disease. Stereotactic radiosurgery (SRS),at&#xD;
      recurrence, has limitations due to the invasive nature of glioblastoma. TTFields may decrease&#xD;
      the tumor aggressiveness outside the target area potentially by multiple pathways, including&#xD;
      immunogenic cell death and DNA repair inhibition sensitizing to radiation. We hypothesize&#xD;
      that combined SRS and TTFields will be complementary, improving outcomes with minimal&#xD;
      toxicity.&#xD;
&#xD;
      In this open-label, phase II trial 40 participants with recurrence will be treated with SRS&#xD;
      and TTFields, starting in 2020. Recurrence will be defined on FET-PET or MRI using RANO&#xD;
      criteria.&#xD;
&#xD;
      All patients will begin treatment within 14 days from baseline imaging evaluation and at&#xD;
      maximum 42 days from screening.&#xD;
&#xD;
      The attempt to obtain the Methyl-guanine methyl-transferase (MGMT) gene promoter methylation&#xD;
      and IDH1 and IDH2 mutation from primary tumor are made during the study whenever not defined&#xD;
      before entering to the study.&#xD;
&#xD;
      TTFields treatment will be initiated as in clinical routine at patients home. Admission to&#xD;
      hospital will not be necessary.&#xD;
&#xD;
      SRS must be delivered within 7 days of TTFields start. A 5-day SRS regimen is allowed.&#xD;
      TTFields should be interrupted only during SRS. The sample size of the study was calculated&#xD;
      for the comparison of survival against a historical control.Overall survival will be&#xD;
      stratified by volume, PET-based treatment, SVZ invasion, MGMT methylation status, time to&#xD;
      first progression, and TTFields compliance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2020</start_date>
  <completion_date type="Anticipated">December 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 9, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open-label, phase II trial enrolling participants with recurrences or progressive tumor, who will be treated with radiosurgery and TTFields. The investigators will attempt to enroll the maximum number of patients and expect to enroll 40 subjects. All subjects will receive TTFields and radiosurgery plus/minus FET PET imaging to define tumor volume.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year survival rate</measure>
    <time_frame>12 Months</time_frame>
    <description>Survival will be measured from date of enrollment until date of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiation necrosis range</measure>
    <time_frame>12 months</time_frame>
    <description>The percentage of patients who had radiation necrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>12 moths</time_frame>
    <description>PFS will be measured from the date of enrollment to date of progression (in months) based on RANO citeria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid needs until treatment failure</measure>
    <time_frame>12 months</time_frame>
    <description>The analysis will be performed based on the steroid doses reported in time of enrollment to date of progression or one year after</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of failure</measure>
    <time_frame>12 months</time_frame>
    <description>The analysis will be performed based on location of failure in relation to target volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rates</measure>
    <time_frame>12 months</time_frame>
    <description>The percentage of patients who had either complete response or partial response per RANO criteria following enrollment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>TTFields and SRS based on MRI or FET-PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive TTFields and radiosurgery plus/minus FET PET imaging to define tumor volume.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTFields and SRS</intervention_name>
    <description>SRS procedure will be delivered within 7 days after start of TTFields therapy . A 5-day SRS regimen is allowed. TTFields should be interrupted in time of SRS and start immediately after.</description>
    <arm_group_label>TTFields and SRS based on MRI or FET-PET</arm_group_label>
    <other_name>Optune, Stereotactic Radiosurgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient's written informed consent (IC) obtained at the latest the day after planning&#xD;
             MRI;&#xD;
&#xD;
          2. Legal capacity: patient can understand the nature, significance, and consequences of&#xD;
             the study;&#xD;
&#xD;
          3. Age ≥18 years (no upper age limit);&#xD;
&#xD;
          4. Karnofsky Performance Score (KPS) ≥ 70;&#xD;
&#xD;
          5. Recurrence of GBM (WHO grade IV) based on RANO criteria or GBM after subtotal&#xD;
             resection of recurrence with macroscopic residual tumor;&#xD;
&#xD;
          6. Histological confirmation of GBM at initial or secondary diagnosis;&#xD;
&#xD;
          7. Previous radiotherapy of glioma with a total dose of 59.4 - 60 Gy (single dose 1.8 -&#xD;
             2.0 Gy) and chemotherapy with temozolomide;&#xD;
&#xD;
          8. At least 6 months between the end of the first course of radiotherapy and&#xD;
             radiosurgery;&#xD;
&#xD;
          9. Recurrent tumor visible on FET-PET and/or T1Gd-MRI, with the maximum diameter up to 5&#xD;
             cm by either technique (in case of multifocal tumors, the sum of all diameters must be&#xD;
             5 cm on FET-PET and T1Gd-MRI);&#xD;
&#xD;
         10. Start of TTFields before radiosurgery;&#xD;
&#xD;
         11. Disease free from other cancers for ≥ 5 years;&#xD;
&#xD;
         12. Adequate haematologic, renal and hepatic function (absolute neutrophil count&#xD;
             ⩾1000/mm3; haemoglobin ⩾100 g/L platelet count, ⩾100,000/mm3; serum creatinine level&#xD;
             ⩽1.7 mg/dL (&lt;150 μmol/L); total serum bilirubin level ⩽ the upper limit of normal and&#xD;
             liver-function values, &lt;3 times the upper limit of normal);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recent (≤ 4 weeks before IC) histological result showing no tumor recurrence;&#xD;
&#xD;
          2. Previous treatment of GBM with bevacizumab;&#xD;
&#xD;
          3. Chemotherapy or molecular targeted therapies planned before diagnosis of further tumor&#xD;
             progression after study intervention&#xD;
&#xD;
          4. Simultaneous participation in other interventional trials which could interfere with&#xD;
             this trial and/or participation in a clinical trial within the last thirty days before&#xD;
             the start of this study and/or previous participation (randomization) in this study;&#xD;
&#xD;
          5. Pregnancy, nursing, or patient not willing to prevent a pregnancy during treatment;&#xD;
&#xD;
          6. Known or persistent abuse of medication, drugs or alcohol;&#xD;
&#xD;
          7. Known allergy against the MRI contrast agent gadolinium or the PET tracer 18F-FET or&#xD;
             against any of the components;&#xD;
&#xD;
          8. Evidence of increased intracranial pressure (midline shift &gt;5 mm, clinically&#xD;
             significant papilledema, vomiting and nausea or reduced level of consciousness);&#xD;
&#xD;
          9. Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other&#xD;
             implanted electronic devices in the brain, or documented clinically significant&#xD;
             arrhythmias.&#xD;
&#xD;
         10. Gross total resection of recurrence confirmed with postoperative MRI and negative&#xD;
             FET-PET result&#xD;
&#xD;
         11. Other malignancies ,except for non-melanomatous skin cancers, or carcinoma in-situ of&#xD;
             uterus, cervix or bladder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maciej Harat, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prof. Franciszek Lukaszczyk Memorial Oncology Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maciej Harat, MD PhD</last_name>
    <phone>+ 48 787 370 610</phone>
    <email>gabinet@onkologharat.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Franciszek Lukaszczyk Oncology Center</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Harat</last_name>
      <phone>+ 48 787 370 610</phone>
      <email>haratm@co.bydgoszcz.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 5, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>January 23, 2021</last_update_submitted>
  <last_update_submitted_qc>January 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prof. Franciszek Lukaszczyk Memorial Oncology Center</investigator_affiliation>
    <investigator_full_name>Maciej Harat</investigator_full_name>
    <investigator_title>dr hab. n. med. Maciej Harat prof. UMK</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>SRS</keyword>
  <keyword>GBM</keyword>
  <keyword>recurrent GBM</keyword>
  <keyword>recurrence</keyword>
  <keyword>stereotactic radiosurgery</keyword>
  <keyword>Radiosurgery</keyword>
  <keyword>FET-PET</keyword>
  <keyword>18F-fluoro-etyl-thyrosine</keyword>
  <keyword>TTFields</keyword>
  <keyword>Optune</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD and all supporting data will be available upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

